Search Clinical Trials
598,193 trials
ID
Status
Phase
Title
Sponsor
NCT07762248
Impact of Minimally Invasive Endodontic Treatment on the Prognosis of Mandibular Permanent Molars With Necrotic Pulp and Apical PeriodontitisMohamed Ashraf AbdeenNot Yet RecruitingPhase 2
NCT07762248Not Yet Recruiting
Phase 2
Impact of Minimally Invasive Endodontic Treatment on the Prognosis of Mandibular...Mohamed Ashraf Abdeen
NCT07764198
A Randomized Controlled Trial of Gabor-Based Perceptual Learning for Adult AmblyopiaJiannan HuangRecruitingNot Applicable
NCT07764198Recruiting
Not Applicable
A Randomized Controlled Trial of Gabor-Based Perceptual Learning for Adult Ambly...Jiannan Huang
NCT07762989
Donor Ankle Sensorimotor Recovery After ACL Reconstruction With a Peroneus Longus Tendon AutograftGazi UniversityNot Yet Recruiting
NCT07762989Not Yet Recruiting
—
Donor Ankle Sensorimotor Recovery After ACL Reconstruction With a Peroneus Longu...Gazi University
NCT07764146
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's DiseaseVoyager TherapeuticsNot Yet RecruitingPhase 1
NCT07764146Not Yet Recruiting
Phase 1
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheim...Voyager Therapeutics
NCT07764328
This Study Aims to Evaluate Whether Milamend's Product Could Improve Hormone Balance in Women Who Suffer From Self-reported PCOS Symptoms.Mila Mend Inc.RecruitingNot Applicable
NCT07764328Recruiting
Not Applicable
This Study Aims to Evaluate Whether Milamend's Product Could Improve Hormone Bal...Mila Mend Inc.
NCT07762144
Clinical Cohort Construction Program of Peking University Third HospitalPeking University Third HospitalEnrolling By Invitation
NCT07762144Enrolling By Invitation
—
Clinical Cohort Construction Program of Peking University Third HospitalPeking University Third H...
NCT07763496
Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical CancerARCAGY/ GINECO GROUPNot Yet RecruitingPhase 2
NCT07763496Not Yet Recruiting
Phase 2
Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical CancerARCAGY/ GINECO GROUP
NCT07764081
Progression, Management, and Clinical Outcomes of Coronary Artery AneurysmsNanjing First Hospital, Nanjing Medical UniversityRecruiting
NCT07764081Recruiting
—
Progression, Management, and Clinical Outcomes of Coronary Artery AneurysmsNanjing First Hospital, N...
NCT07762001
Phase 1 Single-blind Placebo-controlled Dose Escalation Safety Study of AD-NP1Arjun Deb, MDActive Not RecruitingPhase 1
NCT07762001Active Not Recruiting
Phase 1
Phase 1 Single-blind Placebo-controlled Dose Escalation Safety Study of AD-NP1Arjun Deb, MD
NCT07762768
Effect of CSIR-Developed High-Protein, Low-Glycaemic Index Rice on Glycaemic Response in Individuals With PrediabetesCSIR National Institute for Interdisciplinary Science and Technology (NIIST), ThiruvananthapuramNot Yet RecruitingNot Applicable
NCT07762768Not Yet Recruiting
Not Applicable
Effect of CSIR-Developed High-Protein, Low-Glycaemic Index Rice on Glycaemic Res...CSIR National Institute f...
NCT07762911
Evaluation of an MRI-based Prostate Cancer Screening Program (VISIONING): 5-Year Follow-up Round (VISIONING III)University Hospital, Basel, SwitzerlandRecruitingNot Applicable
NCT07762911Recruiting
Not Applicable
Evaluation of an MRI-based Prostate Cancer Screening Program (VISIONING): 5-Year...University Hospital, Base...
NCT07763145
Effect of Citicoline on Neurological Severity Score and Cerebral Doppler Resistive Index in Neonatal Hypoxic Ischemic Encephalopathy: A Randomized Control TrialHayatabad Medical ComplexNot Yet RecruitingNot Applicable
NCT07763145Not Yet Recruiting
Not Applicable
Effect of Citicoline on Neurological Severity Score and Cerebral Doppler Resisti...Hayatabad Medical Complex
NCT07763938
CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell MalignanciesNanjing Legend Biotech Co.Not Yet RecruitingPhase 1
NCT07763938Not Yet Recruiting
Phase 1
CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relap...Nanjing Legend Biotech Co...
NCT07762586
Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC)Rutgers, The State University of New JerseyRecruitingPhase 2
NCT07762586Recruiting
Phase 2
Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NA...Rutgers, The State Univer...
NCT07763093
Vertically Coronally Advanced Flap Versus Coronally Advanced Flap for Miller Class I Gingival RecessionUniversity of Medicine and Pharmacy at Ho Chi Minh CityActive Not RecruitingNot Applicable
NCT07763093Active Not Recruiting
Not Applicable
Vertically Coronally Advanced Flap Versus Coronally Advanced Flap for Miller Cla...University of Medicine an...
NCT07761988
The FamilyStrong Pilot Randomized TrialAmerican Cancer Society, Inc.Not Yet RecruitingNot Applicable
NCT07761988Not Yet Recruiting
Not Applicable
The FamilyStrong Pilot Randomized TrialAmerican Cancer Society,...
NCT07762313
An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular Conduit in Adolescents With Extremity Arterial Injury.Humacyte, Inc.Not Yet RecruitingPhase 3
NCT07762313Not Yet Recruiting
Phase 3
An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular...Humacyte, Inc.
NCT07762547
Evaluating Antiplatelet and Physical Therapy for Slowing Progression in Mild Moyamoya Disease.Beijing Tiantan HospitalNot Yet RecruitingNot Applicable
NCT07762547Not Yet Recruiting
Not Applicable
Evaluating Antiplatelet and Physical Therapy for Slowing Progression in Mild Moy...Beijing Tiantan Hospital
NCT07763249
Comparison of Paravertebral Versus Epidural Block for Post-thoracotomy Pain ControlHospital de Clinicas de Porto AlegreNot Yet RecruitingNot Applicable
NCT07763249Not Yet Recruiting
Not Applicable
Comparison of Paravertebral Versus Epidural Block for Post-thoracotomy Pain Cont...Hospital de Clinicas de P...
Result Breakdown
Not yet recruiting12 (60%)
Recruiting5 (25%)
Active, not recruiting2 (10%)
Enrolling by invitation1 (5%)
not_applicable9 (45%)
Phase 24 (20%)
Not Specified3 (15%)
Phase 13 (15%)
Phase 31 (5%)